Dillon & Associates Inc Novo Nordisk A S Transaction History

Dillon & Associates Inc

  • $637 Million
  • Q1 2024

A detailed history of Dillon & Associates Inc transactions in Novo Nordisk A S stock. As of the latest transaction made, Dillon & Associates Inc holds 277,827 shares of NVO stock, worth $39.7 Million. This represents 5.59% of its overall portfolio holdings.

Number of Shares
277,827
Previous 274,008 1.39%
Holding current value
$39.7 Million
Previous $28.2 Million 26.0%
% of portfolio
5.59%
Previous 5.12%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024
BUY
$102.11 - $135.92 $389,958 - $519,078
3,819 Added 1.39%
277,827 $35.6 Million
Q4 2023

Feb 08, 2024
SELL
$87.78 - $105.45 $743,408 - $893,056
-8,469 Reduced 3.0%
274,008 $28.2 Million
Q3 2023

Nov 13, 2023
BUY
$90.94 - $199.54 $13.3 Million - $29.1 Million
145,739 Added 106.58%
282,477 $25.7 Million
Q2 2023

Aug 08, 2023
SELL
$155.98 - $172.65 $486,501 - $538,495
-3,119 Reduced 2.23%
136,738 $22.2 Million
Q1 2023

May 02, 2023
SELL
$132.34 - $159.14 $952,053 - $1.14 Million
-7,194 Reduced 4.89%
139,857 $22.2 Million
Q1 2023

May 01, 2023
BUY
$132.34 - $159.14 $309,013 - $371,591
2,335 Added 1.61%
147,051 $23.4 Million
Q4 2022

Feb 06, 2023
SELL
$102.55 - $135.33 $14,562 - $19,216
-142 Reduced 0.1%
144,716 $19.5 Million
Q3 2022

Nov 08, 2022
SELL
$95.28 - $116.93 $30,489 - $37,417
-320 Reduced 0.22%
144,858 $14.5 Million
Q2 2022

Jul 26, 2022
SELL
$103.24 - $121.81 $68,448 - $80,760
-663 Reduced 0.45%
145,178 $16.1 Million
Q1 2022

May 06, 2022
SELL
$93.1 - $112.54 $112,651 - $136,173
-1,210 Reduced 0.82%
145,841 $16.2 Million
Q4 2021

Feb 14, 2022
SELL
$95.88 - $117.08 $26,846 - $32,782
-280 Reduced 0.19%
147,051 $16.5 Million
Q3 2021

Oct 28, 2021
SELL
$84.42 - $106.62 $7,091 - $8,956
-84 Reduced 0.06%
147,331 $14.1 Million
Q2 2021

Aug 02, 2021
SELL
$67.66 - $84.76 $87,349 - $109,425
-1,291 Reduced 0.87%
147,415 $12.4 Million
Q1 2021

May 10, 2021
BUY
$67.06 - $75.82 $285,340 - $322,614
4,255 Added 2.95%
148,706 $9.96 Million
Q4 2020

Feb 12, 2021
BUY
$63.89 - $73.8 $278,496 - $321,694
4,359 Added 3.11%
144,451 $10.1 Million
Q3 2020

Nov 06, 2020
BUY
$63.69 - $70.22 $401,692 - $442,877
6,307 Added 4.71%
140,092 $9.67 Million
Q2 2020

Jul 28, 2020
BUY
$58.54 - $67.94 $22,362 - $25,953
382 Added 0.29%
133,785 $8.7 Million
Q1 2020

May 07, 2020
BUY
$49.46 - $64.78 $196,009 - $256,723
3,963 Added 3.06%
133,403 $8 Million
Q4 2019

Feb 03, 2020
SELL
$49.86 - $58.26 $79,277 - $92,633
-1,590 Reduced 1.21%
129,440 $7.51 Million
Q3 2019

Oct 25, 2019
SELL
$47.54 - $53.43 $3,803 - $4,274
-80 Reduced 0.06%
131,030 $6.81 Million
Q2 2019

Jul 22, 2019
SELL
$46.79 - $52.47 $40,426 - $45,334
-864 Reduced 0.65%
131,110 $6.69 Million
Q1 2019

May 07, 2019
SELL
$46.36 - $52.63 $42,883 - $48,682
-925 Reduced 0.7%
131,974 $6.86 Million
Q4 2018

Feb 14, 2019
SELL
$41.54 - $47.25 $281,641 - $320,355
-6,780 Reduced 4.85%
132,899 $6.11 Million
Q3 2018

Nov 14, 2018
SELL
$46.76 - $51.24 $131,068 - $143,625
-2,803 Reduced 1.97%
139,679 $6.57 Million
Q2 2018

Aug 08, 2018
SELL
$44.29 - $50.42 $9,345 - $10,638
-211 Reduced 0.15%
142,482 $6.55 Million
Q1 2018

May 08, 2018
SELL
$48.49 - $58.14 $14,547 - $17,442
-300 Reduced 0.21%
142,693 $6.99 Million
Q4 2017

Feb 08, 2018
BUY
$47.53 - $53.73 $2,376 - $2,686
50 Added 0.03%
142,993 $7.72 Million
Q3 2017

Nov 13, 2017
BUY
$41.15 - $49.22 $22,550 - $26,972
548 Added 0.38%
142,943 $6.86 Million
Q2 2017

Aug 09, 2017
BUY
N/A
142,395
142,395 $6.12 Million

Others Institutions Holding NVO

# of Institutions
1,856
Shares Held
309M
Call Options Held
5.29M
Put Options Held
4.93M
View Full List

About NOVO NORDISK A S

NVO Quotes by TradingView
  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $323B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Dillon & Associates Inc Portfolio

Follow Dillon & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dillon & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Dillon & Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email